Antibody Drug Conjugates

Dear Colleagues,

Antibody drug conjugates (ADCs) are a promising class of biotherapeutics for treatment of diseases such as cancer.  Pairing potent drugs with antibodies through covalent attachment generates a unique therapeutic molecule, where the antibody provides cell-selectivity and extended serum half-life while the drug provides a potent inhibitor of metabolism. “Piggybacking” potent small molecule drugs onto large antibody carriers has allowed new drugs to be used for cancer treatment (such as auristatins, tubulysins, PBDs, and duocarmycins) that present challenges as small molecule therapies alone. Recently fueled by the clinical success of Kadcyla and Adcetris, research efforts continue to improve and refine the ADC platform through identification of new targets, control of drug load, optimizing the site of drug attachment and/or other changes in components that make up the ADC.

This Special Issue of Antibodies focuses on recent advances in ADC technology – including; drug-linker design, warhead selection, conjugation approaches, characterization, pharmacokinetics, biodistribution, antibody engineering, target selection, clinical manifestation and other aspects related to ADCs.

We look forward to receiving your submission to this Special Issue of Antibodies.

Best Wishes,

Dr. R. James (Jim) Christie  
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.